JTCS Speed Up Your Browser
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Anoar Zacharias
Thomas A. Schwann
Christopher J. Riordan
Samuel J. Durham
Aamir Shah
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Habib, R. H.
Right arrow Articles by Shah, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Habib, R. H.
Right arrow Articles by Shah, A.
Related Collections
Right arrow Cardiac - physiology
Right arrow Extracorporeal circulation

J Thorac Cardiovasc Surg 2003;125:1438-1450
© 2003 The American Association for Thoracic Surgery


Cardiopulmonary Support and Physiology

Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: Should current practice be changed?

Robert H. Habib, PhDa,b,c, Anoar Zacharias, MDa,b,c, Thomas A. Schwann, MDa,b,c, Christopher J. Riordan, MDa,b,c, Samuel J. Durham, MDa,b,c, Aamir Shah, MDa,b,c

From Cardiovascular Surgery,a St Vincent Mercy Medical Center, Toledo, Ohio, Saint Luke's Hospital,b Maumee, Ohio; and the Department of Surgery,c Medical College of Ohio, Toledo, Ohio.

Received for publication Feb 12, 2002. Revision requested May 24, 2002; revisions received Aug 21, 2002. Accepted for publication Aug 26, 2002. Address for reprints: Robert H. Habib, PhD, Director, Cardiopulmonary Research, St Vincent Mercy Medical Center, 2213 Cherry St, ACC Building, Suite 309, Toledo, OH 43608 (E-mail: Robert_Habib{at}mhsnr.org).


    Abstract
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
Background: Hemodilutional anemia during cardiopulmonary bypass can lead to inadequate oxygen delivery and, consequently, to ischemic organ injury. In adult bypass, the nadir hematocrit can vary widely with body size and prebypass hematocrit variations, yet its effects on perioperative organ dysfunction and patient outcomes remain largely unknown.
Methods: To elucidate these effects, we retrospectively analyzed operative results and resource utilization data from 5000 consecutive cardiac operations with cardiopulmonary bypass performed on adults (1994 to 2000). Rolling decile groups (500 patients each; 75% overlapping) of increasing lowest hematocrit values were used to characterize hemodilution-outcome relationships. Intermediate-term (0 to 6 years) survival was assessed for coronary artery bypass patients (n = 3800) via Kaplan-Meier analysis in quintile subgroups based on lowest hematocrit. Multivariate logistic regression (operative mortality and morbidity) and Cox proportional hazard model (0- to 6-year mortality) analyses were used to determine independent predictors of poor outcomes.
Results: Stroke, myocardial infarction, low cardiac output, cardiac arrest, renal failure, prolonged ventilation, pulmonary edema, reoperation due to bleeding, sepsis, and multiorgan failure were all significantly and systematically increased as lowest hematocrit value decreased below 22%. Consequently, intensive care requirements, hospital stays, operative costs, and operative deaths were also significantly greater as a function of hemodilution severity. Longer-term survival was improved systematically for increasing lowest hematocrit coronary artery bypass grafting quintiles; for example, 6-year survival was 80.5% and 92.3% for quintiles I (lowest hematocrit = 16.1%) and V (lowest hematocrit = 27.5%). The continuous variable lowest hematocrit was an independent predictor of (1) operative mortality, (2) prolonged cardiovascular intensive case (>2 days) and postoperative hospital (>8 days) stays, and (3) worse 0- to 6-year survival.
Conclusions: Increased hemodilution severity during cardiopulmonary bypass was associated with worse perioperative vital organ dysfunction/morbidity and increased resource use, as well as greater short- and intermediate-term mortality. We speculate that these results derive from inadequate oxygen delivery causing ischemic and/or inflammatory vital organ injury, as recently demonstrated intravitally in cerebral tissues. Although this analysis of a large observational study offers evidence linking low on-pump hematocrit values to these adverse outcomes, prospective randomized trials are needed (1) to establish whether a causal effect of hemodilution on poor outcomes actually exists and (2) to test the potential efficacy of maintaining on-pump hematocrit above 22% for improving outcomes of cardiopulmonary bypass.


    Introduction
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
The Boston groupGo 1 headed by Jonas recently demonstrated, in an intravital animal model, that perfusion of the cerebral microcirculation is not impaired by high hematocrit value (30%) during cardiopulmonary bypass (CPB) compared with moderate (20%) or low (10%) hematocrit value. They also reported evidence of increasingly inadequate cerebral tissue oxygenation and greater white cell-endothelial activation as hematocrit values during CPB decreased.Go 1 Finally, the authors proposed that their intravital results of increased ischemia and inflammatory tissue injury with greater hemodilution explained earlier findings of improved neurological outcomes with high hematocrit.Go Go 2,3

Arguably, the above results may have significant implications to current CPB practice as they contradict prevailing cardiac surgical dogma and current recommendations of textbooksGo Go 4,5, that is, that lower hematocrit values (≤20%) minimize microcirculatory disturbances during CPB and hence will improve tissue perfusion and oxygen delivery. Additionally, if these findings in the cerebral microcirculation prevail in other capillary beds, then milder hemodilution may similarly lead to improved post-CPB outcomes of other vital organs.

In adult CPB, variations of body size and pre-CPB hematocrit, coupled with the essentially constant bypass circuit volume, inevitably lead to wide interpatient variability of the nadir on-pump hematocrit.Go 6 The primary objective of this study was to elucidate the effects of varying "lowest hematocrit" during CPB on postoperative organ dysfunction and patient outcomes. We therefore determined in a large contemporary cardiac surgery series (with CPB) the incidence of serious complications, operative mortality, and resource utilization in terms of varying lowest hematocrit. Also, for isolated coronary artery bypass grafting (CABG), we probed whether and how potential adverse effects of lowest hematocrit levels alter long-term outcomes.


    Methods
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
Patients

With approval of the St Vincent Mercy Medical Center (Toledo, Ohio) Human Investigation Committee, we analyzed the clinical outcomes of 5000 consecutive adult cardiac surgery patients from a single institution (1994-2000). Standard CPB techniques were applied with predominant (96%) use of normothermia (body temperature: 35°C to 37°C).Go 6 Arterial blood flow was determined on the basis of a cardiac index of 2.5 to 3.0 (L · min-1 · m-2), and mean arterial pressure was maintained at greater than 60 mm Hg. All surgeons used standardized clinical care pathway protocols.

Data Collection

Risk factors, CPB variables, complications, and operative mortality (OM; in-hospital death or <30 days out-of-hospital death) data were collected in a dedicated database. Cardiovascular intensive care unit (CVICU) and postoperative length of stays (LOS) were entered for all patients in the same database. Total direct variable costs (Cost) were compiled for patients from 1997 to 2000, and these encompassed every care-related expense throughout the admission period.Go 7 Cost data are presented in terms of the annual average cost to correct for inflation.

The social security death index database (http://ssdi.geneology.rootsweb.com) was queried in October 2001 for each patient via individual searches to verify accurate out-of-hospital death data. This resulted in survival follow-up data for all patients ranging from up to 8 to 93 months. Our database was updated for any missing late mortality data.

Data Analysis/Statistical Methods

Univariate analyses. Lowest hematocrit is a continuous normally distributed variable, and examining its effects on "dichotomous" outcome measures (eg, mortality [yes/no]) can hinge on how the population is subdivided.Go 6 Multiple steps were applied to identify outcomes associated to the extent of hemodilution on CPB. First, mean lowest hematocrit values of each complicated subgroup (eg, stroke) were compared with patients free of any complications. Next, incidence of each complication was compared among lowest hematocrit quintile groups (n = 1000 each). Finally, we derived continuous independent variable-outcome relations by consideration of rolling decile subgroups.Go 6 Here, patient data were first arranged in increasing lowest hematocrit order, and a total of 37 subgroups (75% overlapping ranges) were separately analyzed, such that group 1 included patients 1 to 500 (0%-10%), group 2 included patients 126 to 625 (2.5%-12.5%), and so on. Note, with this method, the smaller subgroup size minimized within-group lowest hematocrit heterogeneity while the 75% overlap smoothed the effects of similar lowest hematocrit values in consecutive subgroups.

Continuous variables were presented as mean ± standard deviation and categorical data were presented as frequency counts (N, %). Nonlinear regression analyses (SPSS, Inc, Chicago, Ill) were used to describe continuous lowest hematocrit-outcome relations. Group comparisons of continuous variables were done using unpaired t test (2 groups) or 1-way analysis of variance (3 or more groups) depending on applicability. {chi}2-Square tests were used for categorical variables. Long-term survival was assessed via Kaplan-Meier and death hazard analyses.Go 8

Multivariate analyses. We used multivariate analyses to determine if and how nadir on-pump hematocrit, among other variables, predicted certain outcomes (length of stay as well as early and late mortality). Also, we determined the pre- and intraoperative variables predicting the extent of hemodilution on CPB, or lowest hematocrit (%), via multiple linear regression analysis (SPSS). All multivariate methods were limited to the 3800 patients who underwent isolated CABG to avoid the possible varying effects on outcomes of valve and or combined operations.

First, predictors of operative mortality and perioperative morbidity were derived via multiple logistic regression (SPSS). We defined perioperative morbidity as patients who remained in excess of 48 hours in cardiovascular intensive care (CVICU > 2 days) or patients with postoperative hospital stays greater than 8 days. Cox proportional hazard models were used to define the effect of explanatory variables (including lowest hematocrit) on 0- to 6-year mortality after CABG with CPB. Model selection was first done with backward elimination and variables significant at the P < .05 level were retained in the model as independent predictors. Models were then confirmed using forward selection and stepwise selection. The considered prognostic variables in the multivariate models were the preoperative and intraoperative variables listed in Table 1 in addition to the categorical variables postoperative transfusion and use of intra-aortic balloon pump.


View this table:
[in this window]
[in a new window]
 
Table 1. Demographics, risk factors, and cardiopulmonary bypass data for all patients and for quintiles (I-V) divided based on lowest hematocrit
 

    Results
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
This CPB series (64 ± 11 years) included 3296 (66%) men and 1704 (34%) women (Table 1Go). Of these, 3800 underwent isolated CABG (76%). The lowest hematocrit value reached during CPB varied widely among patients (21.4 ± 4.2%, median = 21.2%, range: 9.1%-40.3%). Lowest hematocrit quintiles show that older age, female sex, diabetes, history of cerebrovascular accidents, preoperative renal failure, peripheral vascular disease, non-CABG, reoperation, nonelective status, and increased time on bypass were all more frequent in more hemodiluted patients (Table 1Go). Alternatively, ejection fraction, chronic obstructive pulmonary disease, left main disease, and three-vessel disease did not vary with this on-pump hematocrit level.

Independent predictors of the nadir hematocrit determined via multivariate linear regression included four continuous (pre-CPB hematocrit value, body surface area, time on CPB, and age) and two categorical (female sex and preoperative renal failure) variables (Table 2). Pre-CPB hematocrit value (%) and body surface area (BSA) were the main determinants of the nadir hematocrit on pump as would be expected based on red blood cell mass balance considerations in conjunction with a constant volume of the CPB crystalloid prime. Alternatively the variations in lowest hematocrit value in terms of age and time on CPB are probably indirect, and reflect (1) the on-average lower pre-CPB hematocrit value (39%-35%) and BSA (2.0-1.8 m2) with increasing CABG patient age (60-80 years) and (2) greater blood loss with prolonged pump times.


View this table:
[in this window]
[in a new window]
 
Table 2. Predictors of lowest hematocrit (%) during CPB derived by forward stepwise multivariate linear regression
 
A total of 181 operative deaths (3.6%) patients were documented in this 5000 CPB patient series, and 975 patients had at least one postoperative complication (19.5%). For the 3800 CABG only patients in this series, as of October 2001, 355 (9.3%) patients were dead (OM: 90 or 2.4%; late: 265 or 6.9%). Time to death was 20 ± 21 months (median = 10; range: 0-79) and follow-up was 53 ± 23 (median = 53, range: 8-93) months.

Effects of Lowest Hematocrit on Outcomes

Operative outcomes. Variations in hemodilution levels for patients, which were divided based on incidence of postoperative complications, are summarized in Table 3. Lowest hematocrit for OM (19.0 ± 4.1%) and complicated (19.9 ± 4.0%) patients were significantly lower than for uncomplicated (21.8 ± 4.1%) patients (unpaired t test). Moreover, this trend was true for all types of complications, and more severe hemodilution was associated with greater likelihood of multiple complications.


View this table:
[in this window]
[in a new window]
 
Table 3. Variations in lowest hematocrit on CPB for complicated patient groups
 
Consistent with the above, analysis of lowest hematocrit based quintiles (Table 4) shows that all measures of morbidity, except for sternal wound infection and acute respiratory distress syndrome, change systematically with the extent of hemodilution (1-way analysis of variance). In brief, for all CPB as well as for isolated CABG (Figure 1), the incidence of reoperation for bleeding (~fivefold), tamponade (~sixfold), perioperative myocardial infarction (~fourfold), cardiac arrest (~fourfold), permanent stroke (~sixfold), coma (~sixfold), prolonged mechanical ventilation (~threefold), pulmonary edema (~fourfold), septicemia (~threefold), use of intra-aortic balloon pump (~fourfold), renal failure (~fourfold), and multiorgan failure (~sevenfold) were all systematically greater as lowest hematocrit value decreased. Note, adverse hemodilution effects were particularly greater for lowest hematocrit value below 22%.


View this table:
[in this window]
[in a new window]
 
Table 4. Postoperative data for all patients and for quintiles (I-V) divided based on lowest hematocrit
 


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1. Incidence of 12 postoperative complications (see specific complication on each plot) reflecting the dysfunction post-CPB of the various vital organs shown plotted in terms of increasing lowest hematocrit for all cardiac surgeries (n = 5000 patients). All types of complications were more frequent as hemodilution severity increased, particularly for lowest hematocrit < 22%. Lines (solid and dashed) represent nonlinear regression approximations of actual trends shown for rolling decile groups as symbols (open and closed, respectively). These trends were similar (albeit not in magnitude) when only isolated CABG patients (n = 3800) are considered (symbols were omitted for clarity). Generally lower incidence of complications in CABG compared to all cardiac operations suggest higher incidence of complications in non-CABG operations with perhaps greater adverse effects of hemodilution.

 
Consequently, CVICU/postoperative LOS and OM varied substantially with lowest hematocrit value (Figure 2). Both hospital stays and OM were generally lower for (1) CABG versus non-CABG patients and (2) younger (≤65 years) versus older (>65 years) patients. Yet, their decreasing trends as lowest hematocrit increased were similar. Multivariate predictors of operative mortality and morbidity (CVICU > 2 days, postoperative LOS > 8 days) as determined by multivariate logistic regression are summarized in Table 5. This analysis showed that, along with other predictors, decreased lowest hematocrit value (%; considered as a continuous variable) is associated with (1) increased operative mortality (risk ratio: 0.863; P < .001), (2) increased likelihood of prolonged intensive care stay (CVICU > 2 days; risk ratio: 0.968; P < .001), and (3) greater likelihood of postoperative hospitalization of 9 or more days (postoperative LOS >8 days; risk ratio: 0.954; P < .001).



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2. Top, CVICU and postoperative hospital stays were systematically and significantly decreased between low (15%) and high (29%) lowest hematocrit overlapping decile groups for all CPB patients (left) and for isolated CABG (right). Bottom, Operative mortality (OM) was systematically and significantly decreased between low (15%) and high (29%) lowest hematocrit overlapping decile groups for all CPB patients (left) and for isolated CABG (right). Although OM is lower in young (dashed, thin lines) compared with older (dashed, thick lines) patients, the relative trends of increased deaths with severity of hemodilution were comparable (lowest hematocrit < 20%) irrespective of age. Bottom right (inset), Observed-to-expected (O/E) mortality decreased systematically and substantially for patient cohorts whose lowest hematocrit value was between 15% and 22% and was relatively unchanged for greater values. Expected mortality was derived from patient data using The Society of Thoracic Surgeons CABG multivariate operative risk model.Go 23. Lines represent nonlinear regression approximations of actual trends shown for rolling decile groups as symbols. These trends were similar in young (dashed, thin lines) and old (dashed, thick lines) patients. Symbols for age subgroups were omitted for clarity.

 

View this table:
[in this window]
[in a new window]
 
Table 5. Predictors of operative mortality and morbidity after CABG by multivariate logistic regression analysis
 
Frequency of intraoperative and postoperative transfusion and the direct variable costs of surgery were strongly related to the severity of hemodilution (Figure 3). Note, the effects of hemodilution on average operative costs were similar for all CPB surgeries or CABG only, and these increased sharply for lowest hematocrit < 20%, while they were unchanged for lowest hematocrit value >24%.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3. Right, Cost of cardiac surgery was systematically and significantly decreased between low (15%) and high (29%) lowest hematocrit overlapping decile groups for all CPB patients (circles) and for isolated CABG (triangles). Lines represent nonlinear regression approximations of actual trends shown for rolling decile groups as symbols. Left, Incidence of transfusion (any, intraoperative, postoperative, and both intraoperative and postoperative) decreased substantially and systematically as a function of hemodilution on pump in cardiac surgery patients, as illustrated for overlapping decile cohorts (500 patients each) from low (15%) to high (29%) lowest hematocrit value during CPB. Compared with nontransfused patients (23.2 ± 3.7 [23.2%]), mean (median) lowest hematocrit values were substantially lower for transfused patients (any: 19.2 ± 3.5 [18.8%]; intraoperative: 18.0 ± 3.2 [17.6%]; postoperative: 19.5 ± 3.6 [19.1%]; both: 17.9 ± 3.2 [17.4%]; all with P < .001 [unpaired t test]).

 
Longer-term outcomes. For all isolated CABG patients combined, the 1-, 3-, and 6-year survival estimates were 95.2%, 92.5%, and 88.1%, respectively. However, longer-term (0-6 years) effects of decreased lowest hematocrit value were also apparent in isolated CABG patients. When separately analyzed, lowest hematocrit value (16.1%-27.5%) CABG quintiles (760 patients each) exhibited increasingly better survival (1-year: 90.1%-97.6%; 3-year: 86.1%-96.0%; and 6-year: 80.5%-92.3%) with decreasing hemodilution severity (Figure 4, top). Moreover, death hazard analysis of the Kaplan-Meier survival curves for CABG patients divided to lowest hematocrit ≤20% (N = 1418) versus >20% (N = 2382) shows systematically greater early as well as late mortality in the more severely hemodiluted group (Figure 4Go, bottom).



View larger version (39K):
[in this window]
[in a new window]
 
Fig. 4. Top, Kaplan-Meier 0- to 6-year survival plots shown for all five CABG lowest hematocrit quintile groups (I to V: n = 760 each). Compared with quintile V (least hemodiluted), survival for quintiles I (P < .001), II (P < .001), and III (P = .002) was significantly worse by log-rank test. Bottom, Comparison of early and late mortality in CABG patients hemodiluted down to 20% or less versus those with lowest hematocrit values >20% as derived by death hazard analysis. Corresponding survival plots (which are implicit from top panel data) are not shown.

 
Results of multivariate Cox proportional hazard model analysis of 0- to 6-year mortality are summarized in Table 6. These showed that decreased lowest hematocrit value (%) is associated with worse survival over this interval (odds ratio: 0.950; P = .001). Other predictors of 0- to 6-year mortality were older age (years), increased time on cardiopulmonary bypass (minutes), lower ejection fraction (%), in addition to four other categorical (yes/no) variables/diagnoses: preoperative renal failure, chronic lung disease, cerebrovascular disease, and peripheral vascular disease.


View this table:
[in this window]
[in a new window]
 
Table 6. Predictors of 0- to 6-year mortality after CABG by multivariate Cox proportional hazard model analysis
 

    Discussion
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
We demonstrated, via a large consecutive adult cardiac surgery series, that adverse outcomes after CPB are systematically increased as a function of hemodilution severity. Specifically, we showed that most major complications, including stroke, myocardial infarction, low cardiac output syndrome (intraoperative/postoperative intra-aortic balloon pump), renal failure, pulmonary edema, reoperation due to bleeding, sepsis, and multiorgan failure, are increased as the nadir hematocrit during CPB decreased (Figure 1Go). Moreover, this hematocrit-complications association inevitably resulted in significantly and systematically greater intensive care requirements, hospital stays, operative costs, and death with increasing levels of hemodilution, particularly for lowest hematocrit value less than 22% (Figures 3Go and 4Go). Indeed, the observed-to-expected (O/E) CABG mortality decreased systematically and substantially for patient cohorts whose lowest hematocrit was between 15% and 22% and was relatively unchanged for greater values (Figure 3Go, bottom right). Lowest hematocrit value (%) was also found to be an independent predictor of operative mortality and morbidity (Table 5Go).



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 5. Analysis of the interaction between the effects of lowest hematocrit (symbols) and two important covariate predictors (time on CPB [minutes] and [b] age [years]) of operative mortality (OM) and morbidity represented by postoperative length of hospital stays (postop LOS). Solid regression lines were used to delineate the changes in OM and postoperative LOS in terms of the predictor variables time on CPB and age for all patients irrespective of hemodilution levels (symbols were not used for visual clarity). Dashed lines in top panels represent regression results describing the (1) OM-time on CPB and (2) OM-age relations for the two hemodilution subgroups. See text for more details.

 
In addition, somewhat unexpectedly, we found that hemodilutional anemia on bypass was associated with long-term adverse effects as well. Specifically, survival trends of lowest hematocrit CABG quintile subgroups (I to V: 760 patients each) were significantly and systematically better with decreasing hemodilution severity (Figure 4Go). For example, 6-year survival was 80.5% for group I patients in whom the average lowest hematocrit value was a low 16.1%. In contrast, groups IV (lowest hematocrit value: 23.6%) and V (lowest hematocrit: 27.5%) both had a 92.3% survival 6 years after CABG. Granted, systematically younger age of patients for group I (67 years) through group V (60 years) and the fact that operative deaths were also greater in the more hemodiluted patients have contributed to the difference in survival. However, this lowest hematocrit effect on intermediate-term survival that is apparent from 0- to 6-year survival and death hazard analyses in CABG patients (Figure 4Go) was confirmed to be an independent predictor by multivariate Cox proportional hazard analysis (Table 6Go).

Other authorsGo Go 9-11 have suggested a possible link between hemodilution on CPB and worse operative outcomes after CABG but, to our knowledge, no studies have previously reported an association between CPB hemodilution levels and worse longer-term outcomes. Consistent with our data, DeFoe and colleaguesGo 9 reported increased reoperation of bleeding and low cardiac output and in-hospital mortality with increased hemodilution severity. They, however, did not find a systematic increase in stroke. Hardy and coworkersGo 10 reported increased postoperative renal failure, hemodynamic instability, and death with decreased hematocrit (1) on pump or (2) during the first 24 hours postoperatively. Fang and colleaguesGo 11 used a multivariate analysis that separated low- and high-risk CABG patients and concluded that hematocrit values below 14% in low-risk patients and 17% in high-risk patients are associated with a doubling of the risk of death. A similar variance was also evident by contrasting our LOS (hematocrit and mortality) hematocrit data for young (lower-risk) versus older (higher-risk) patients (Figure 2Go). These showed that worse outcomes occur at relatively lower hematocrit valuesin young (20%) compared with older (22% to 24%) patients indicating a varying tolerance of hemodilution on CPB.

In this series, we report associations between hemodilution levels and a large number of complications, as well as a number of morbidity and mortality measures. An obvious reason for this is that more outcome variables were included in the analysis. We also contend that this was facilitated by the consideration of lowest hematocrit as a continuous variable as opposed to use of arbitrary hematocrit values to define patient cohorts. Also, via the overlapping deciles analyses one is able to better define the continuous relations between on-pump hemodilutional anemia and specific postoperative complications, resource use, and death.

Roach and colleaguesGo 12 recently reported that adverse neurologic events of varying severity are unfortunately among the most frequent complications of CPB. Moreover, Newman and coworkersGo 13 showed a relatively high prevalence and persistence of neurocognitive deficits after CABG. To our knowledge, the substantial dependence of the incidence of stroke on lowest hematocrit is the first such reported association in adult cardiac surgery. This perhaps implicates hemodilution severity as a primary cause of CPB adverse neurologic effects. Importantly, this agrees with experimental findings of reduced cerebral oxygen deliveryGo Go Go 1,14-19 and worse neurologic outcomesGo Go 2,3 with low hematocrit on CPB. Indeed, in case of normothermic CPB, Liam and colleaguesGo 19 showed using a dog model that both oxygen delivery and whole body oxygen uptake were reduced when hematocrit values fell below 25%, becoming significant at 18% or below. They further concluded that (1) hematocrit levels above 18% were needed to maintain oxygen delivery and consumption, (2) the critical hematocrit value may be higher for bypass compared with nonbypass hemodilution states, and (3) the critical hematocrit value for the body appears to be higher than that required for the brain during warm bypass, presumably because the brain is more effective at increasing its flow in hemodiluted states. Interestingly, the experimental data of Liam and colleaguesGo 19 agrees with our clinical data, which showed little or no adverse effects of hemodilution when hematocrit values did not fall below the 21% to 22% levels (Figure 2Go). This critical hematocrit falls within the 25% and 18% hematocrit values identified by them for adequate versus compromised oxygenation, respectively.

A number of large studies have convincingly shown that small size and female (who are small relative to males) patients have worse outcomes of CPB including greater OM.Go Go Go Go Go 6,9,10,20-22 We believe that the poor outcomes in these two patient subpopulations are directly linked to their relatively more severe hemodilution during CPB. In this series, OM was significantly greater in female and low-BSA patient subpopulations, both of which were characterized by significantly (P < .001) lower nadir hematocrit values on pump: (1) female compared with male patients [OM: 3.3% (39/1175), lowest hematocrit: 18.7 ± 3.9% vs 1.9% (51/2625), 23.1 ± 3.1%] and (2) small-size (BSA ≤ 1.8 m2) compared with larger-size (BSA > 1.8 m2) patients [3.9% (33/846), 18.4 ± 3.2% vs 1.9% (57/2954), 22.7 ± 3.9%].

Prolonged time on cardiopulmonary bypass (>100 minutes) and increased age are also established major determinants of increased morbidity and mortality after CABG,Go 23a fact confirmed in this series as well. In addition, we have found that severity of hemodilution during cardiopulmonary bypass as defined by the nadir on-pump hematocrit is a strong predictor of increased CABG morbidity (Figures 3Go and 4Go, Table 5Go) and mortality (Figure 2Go, Table 5Go). Yet, the extent to which hemodilution severity alters observed operative outcomes in relation to patient age and duration of bypass is not known. We thus compared the incidence of OM and postoperative hospital stays (POLOS) in (1) age and (2) time on CPB patient decile groups (380 patients each). Here, within each decile group, OM and POLOS were contrasted for patients whose nadir hematocrit dropped to 21% or less versus those with lowest hematocrit values greater than 21% (Figure 5). Irrespective of age and duration of CPB, we found substantial and systematically increased poorer outcomes (OM and POLOS) in the more hemodiluted patients. Moreover, this hemodilution effect on OM tended to be greater in patients who are over 70 years and/or those who remained on bypass for 2 or more hours. Although it remains to be proven by prospective studies, these findings do suggest that the possibility of improved operative outcomes if hemodilution to levels below 21% is avoided during CPB and that older patients and prolonged cardiopulmonary bypass patients might benefit most from such control of on-pump hematocrit levels. Finally, the tendency of greater OM variance with hematocrit value with longer pump runs is suggestive of a dose effect of on-pump hemodilution (ie, adverse effects of the same low [<21%] nadir hematocrit may be increased as the duration of bypass increases).

If the aforementioned associations between low hematocrit levels on CPB and worse outcomes obtained by the reported univariate and multivariate analyses are shown to be causal by prospective randomized studies, then methods aimed at minimizing on-pump hemodilutional anemia (eg, lowest hematocrit ≥ 22%) might lead to significant improvements in patients at risk. Note, hematocrit value during CPB is an intraoperative variable that cardiac surgeons can potentially control so that adverse outcomes are minimized in contrast to preoperative variables over which they have little or no control and, ironically, these have been traditionally the focus of quality improvement.

Hemodilution during CPB results from the mixing of pump crystalloid and colloid prime solution with the patient's blood, and these two relative volumes, along with pre-CPB hematocrit, will largely determine the nadir hematocrit (Table 2Go). In that sense, lowest hematocrit value during CPB is then a potentially modifiable risk factor. Changes to several areas of practice in CPB patients can alter the extent of hemodilution experienced in a given patient. These include controlling preoperative blood loss during routine phlebotomy and cardiac catheterization; possible redesign and use of variable-size, or multiple sizes of, CPB circuits to be used according to patient BSA; minimizing of the tubing size (length and diameter) connecting the patient and pump; more timely return of collected cells to the circulating volumes; more strict control of intraoperative blood loss and fluid administration; use of retrograde autologous priming of the CPB circuit, which has been shown to reduce hemodilution and transfusion requirementsGo Go 24,25; and, lastly, freer use of blood transfusions during CPB so as to maintain hematocrit at predetermined levels. The latter is perhaps the most controversial of the above recommendations. Yet, as Figure 3Go shows, a large fraction of the more hemodiluted patients are transfused anyway. Moreover, at a minimum, our data raises the prospect that adverse transfusion effects in CPB patients derive, in a significant way, from the associated on-pump hemodilution as opposed to being a consequence of transfusion per se. Obviously, this question will only be resolved by appropriate prospective studies.

In conclusion, we found strong systematic associations between severity of hemodilution on CPB and serious complications affecting most major vital organs; particularly when the nadir hematocrit drops below 22%. Expectedly, these associations then lead to (1) increased resource utilization such as CVICU/hospital stays and operative costs and, more importantly, (2) substantially greater operative mortality. We also found evidence of potential long-term effects of on-pump hemodilutional injury to vital organs as manifested by the worse 0- to 6-year survival due to a sustained increase in death hazard after CPB in the more severely hemodiluted patients. We believe these data represent compelling evidence of substantially greater adverse outcomes when hematocrit value during CPB is allowed to fall below a critical value (~22%) and hence warrant future prospective confirmatory investigation that should also aim to separate the correlated effects of substantial hemodilution on bypass and transfusion of blood products. We further speculate that these adverse effects might have as common mechanisms (1) ischemic vital organ tissue injury within vital organs due to inadequate oxygen delivery at low hematocrits, and (2) systemic inflammatory injury due to increased white cell-endothelial activation in microcirculatory beds of vital organs. These hemodilution effects during CPB per se have been convincingly demonstrated in recent experimental studies by the Boston groupGo Go 1-3 and by Cook, Daly, and coworkers.Go Go Go 14-16,19


    Acknowledgments
 
We thank Mike Evans and Sue Harvan (perfusionists) for their valuable assistance in collection of the cardiopulmonary bypass data.


    References
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 

  1. Duebener LF, Sakamoto T, Hatsuoka S, Stamm C, Zurakowski D, Vollmar B, et al. Effects of hematocrit on cerebral microcirculation and tissue oxygenation during deep hypothermic bypass. Circulation. 2001;104(Suppl I):I-260-4.
  2. Shin'oka T, Shum-Tim D, Jonas RA, Lidov HG, Laussen PC, Miura T, et al. Higher hematocrit improves cerebral outcome after deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 1996;112:1610-20.[Abstract/Free Full Text]
  3. Shin'oka T, Shum-Tim D, Laussen PC, Zinkovsky SM, Lidov HG, du Plessis A, et al. Effects of oncotic pressure and hematocrit on outcome after circulatory arrest. Ann Thorac Surg. 1998;65:155-64.[Abstract/Free Full Text]
  4. Kirklin JW, Barratt-Boyes BG. Hypothermia, circulatory arrest and cardiopulmonary bypass. In: Cardiac surgery. New York: Churchill Livingstone; 1993. p. 62-73.
  5. Cooper MM, Elliot MJ. Haemodilution. In: Jonas RA, Elliot MJ, editors. Cardiopulmonary bypass in neonates, infants and young children. Oxford, UK: Butterworth-Heinemann, 1994. p. 82-99.
  6. Schwann TA, Habib RH, Zacharias A, Parenteau GL, Riordan CJ, Durham SJ, et al. Effects of body size on operative, intermediate and long-term outcomes after coronary artery bypass operation. Ann Thorac Surg. 2001;71:521-31.[Abstract/Free Full Text]
  7. Riordan CJ, Engoren M, Zacharias A, Schwann TA, Parenteau GL, Durham SJ, et al. Resource utilization in coronary artery bypass surgery: does surgical risk predict cost? Ann Thorac Surg. 2000;69:1092-7.[Abstract/Free Full Text]
  8. Blackstone EH. Analysis of death (survival analysis) and other time-related events. In: FT Macartney, editor. Current status of clinical cardiology. Congenital Heart Disease. Lancaster: MTP Press, 1986. p. 55-101.
  9. DeFoe GR, Ross CS, Olmstead EM, Surgenor SD, Fillinger MP, Groom RC, et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 2001;71:769-76.[Abstract/Free Full Text]
  10. Hardy JF, Martineau R, Couturier A, Belisle S, Cartier R, Carrier M. Influence of haemoglobin concentration after extracorporeal circulation on mortality and morbidity in patients undergoing cardiac surgery. Br J Anaesth. 1998;81(Suppl 1):38-45.[Free Full Text]
  11. Fang WC, Helm RE, Krieger KH, Rosengart TK, DuBois WJ, Sason C, et al. Impact of minimum hematocrit during cardiopulmonary bypass on mortality in patients undergoing coronary artery surgery. Circulation. 1997;96:SII194-9.
  12. Roach GW, Kanchuger M, Mangano CM, Newman M, Nussmeier N, Wolman R, et al. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. N Engl J Med. 1996;335:1857-63.[Abstract/Free Full Text]
  13. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Gorcott H, Jones RH, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001;344:395-402.[Abstract/Free Full Text]
  14. Cook DJ, Oliver WC Jr, Orszulak TA, Daly RC, Bryce RD. Cardiopulmonary bypass temperature, hematocrit, and cerebral oxygen delivery in humans. Ann Thorac Surg. 1995;60:1671-7.[Abstract/Free Full Text]
  15. Cook DJ, Orszulak TA, Daly RC. Minimum hematocrit at differing cardiopulmonary bypass temperatures in dogs. Circulation. 1998;98:SII170-4 [discussion II175].
  16. Cook DJ, Orszulak TA, Daly RC, MacVeigh I. Minimum hematocrit for normothermic cardiopulmonary bypass in dogs. Circulation. 1997;96:SII200-4.
  17. Nomura F, Naruse H, duPlessis A, Hiramatsu T, Forbess J, Holtzman D, et al. Cerebral oxygenation measured by near infrared spectroscopy during cardiopulmonary bypass and deep hypothermic circulatory arrest in piglets. Pediatr Res. 1996;40:790-6.[Medline]
  18. Langley SM, Chai PJ, Tsui SS, Jaggers JJ, Ungerleider RM. The effects of a leukocyte-depleting filter on cerebral and renal recovery after deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2000;119:1262-9.[Abstract/Free Full Text]
  19. Liam BL, Plöchl W, Cook DJ, Orszulak TA, Daly RC. Hemodilution and whole body oxygen balance during normothermic cardiopulmonary bypass in dogs. J Thorac Cardiovasc Surg. 1998;115:1203-8.[Abstract/Free Full Text]
  20. Aldea GS, Gaudiani JM, Shapira OM, Jacobs AK, Weinberg J, Cupples AL, et al. Effect of gender on postoperative outcomes and hospital stays after coronary artery bypass grafting. Ann Thorac Surg. 1999;67:1097-103.[Abstract/Free Full Text]
  21. O'Connor GT, Morton JR, Diehl MJ, Olmstead EM, Coffin LH, Levy DG, et al. Differences between men and women in hospital mortality associated with coronary artery bypass graft surgery. The Northern New England Cardiovascular Disease Study Group. Circulation. 1993;88:2104-10.[Abstract/Free Full Text]
  22. Birkmeyer NJ, Charlesworth DC, Hernandez F, Leavitt BJ, Marrin CA, Morton JR, et al. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation. 1998;97:1689-94.[Abstract/Free Full Text]
  23. Edwards FH, Grover FL, Shroyer ALW, Schwartz M, Bero J. The Society of Thoracic Surgeons national cardiac surgery database: current risk assessment. Ann Thorac Surg. 1997;63:903-8.[Abstract/Free Full Text]
  24. Rosengart TK, Debois W, O'Hara M, et al. Retrograde autologous priming for cardiopulmonary bypass. A safe and effective means of decreasing hemodilution and transfusion requirements. J Thorac Cardiovasc Surg. 1998;115:426-39.[Abstract/Free Full Text]
  25. Subramaniam B, Cross MH, Karthikeyan S, Mulpur A, Hansbro SD, Hobson P. Retrograde autologous priming of the cardiopulmonary bypass circuit reduces blood transfusion after coronary artery surgery. Ann Thorac Surg. 2002;73:1912-8.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Anesth. Analg.Home page
R. A. J. M. Huybregts, R. de Vroege, E. K. Jansen, A. W. van Schijndel, H. M. T. Christiaans, and W. van Oeveren
The Association of Hemodilution and Transfusion of Red Blood Cells with Biochemical Markers of Splanchnic and Renal Injury During Cardiopulmonary Bypass
Anesth. Analg., August 1, 2009; 109(2): 331 - 339.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
A. Castiglioni, A. Verzini, N. Colangelo, S. Nascimbene, G. Laino, and O. Alfieri
Comparison of minimally invasive closed circuit versus standard extracorporeal circulation for aortic valve replacement: a randomized study
Interactive CardioVascular and Thoracic Surgery, July 1, 2009; 9(1): 37 - 41.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
F. De Somer
Optimal Versus Suboptimal Perfusion During Cardiopulmonary Bypass and the Inflammatory Response
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2009; 13(2): 113 - 117.
[Abstract] [PDF]


Home page
Anesth. Analg.Home page
G. S. Murphy, E. A. Hessel II, and R. C. Groom
Optimal Perfusion During Cardiopulmonary Bypass: An Evidence-Based Approach
Anesth. Analg., May 1, 2009; 108(5): 1394 - 1417.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
V. Kasirajan, L. G. Wolfe, and A. Medina
Adverse influence of female gender on outcomes after coronary bypass surgery: a propensity matched analysis
Interactive CardioVascular and Thoracic Surgery, April 1, 2009; 8(4): 408 - 411.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Ranucci
Minimal Extracorporeal Circulation: The Real Impact on Postoperative Outcome
Ann. Thorac. Surg., January 1, 2009; 87(1): 352 - 353.
[Full Text] [PDF]


Home page
PerfusionHome page
H Vermeer, S Teerenstra, R. de Sevaux, H. van Swieten, and P. Weerwind
The effect of hemodilution during normothermic cardiac surgery on renal physiology and function: a review
Perfusion, November 1, 2008; 23(6): 329 - 338.
[Abstract] [PDF]


Home page
Anesth. Analg.Home page
G. M. T. Hare, A. K. Y. Tsui, A. T. McLaren, T. E. Ragoonanan, J. Yu, and C. D. Mazer
Anemia and Cerebral Outcomes: Many Questions, Fewer Answers
Anesth. Analg., October 1, 2008; 107(4): 1356 - 1370.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. A.J.M. Huybregts, R. de Vroege, and W. van Oeveren
A New System for Right Atrial Cooling
Ann. Thorac. Surg., April 1, 2008; 85(4): 1421 - 1424.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Ranucci, A. Pazzaglia, C. Bianchini, G. Bozzetti, and G. Isgro
Body Size, Gender, and Transfusions as Determinants of Outcome After Coronary Operations
Ann. Thorac. Surg., February 1, 2008; 85(2): 481 - 486.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Karkouti, D. N. Wijeysundera, W. S. Beattie, and for the Reducing Bleeding in Cardiac Surgery (RBC)
Risk Associated With Preoperative Anemia in Cardiac Surgery: A Multicenter Cohort Study
Circulation, January 29, 2008; 117(4): 478 - 484.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
M. Ranucci
Perioperative Renal Failure: Hypoperfusion During Cardiopulmonary Bypass?
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 265 - 268.
[Abstract] [PDF]


Home page
CirculationHome page
G. J. Murphy, B. C. Reeves, C. A. Rogers, S. I.A. Rizvi, L. Culliford, and G. D. Angelini
Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery
Circulation, November 27, 2007; 116(22): 2544 - 2552.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
J. K. Shoemaker
Hemodilution Impairs Cerebral Autoregulation, Demonstrating the Complexity of Integrative Physiology
Anesth. Analg., November 1, 2007; 105(5): 1179 - 1181.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. H. Habib, A. Zacharias, and T. A. Schwann
Minimally Invasive Closed Circuit Versus Standard Cardiopulmonary Bypass: Is It Renoprotective?
Ann. Thorac. Surg., October 1, 2007; 84(4): 1426 - 1427.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. H. Habib and A. Zacharias
Body Size and the Early Mortality Gender Gap in Coronary Artery Bypass Grafting Surgery
J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1095 - 1095.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. H. Humphries, M. Gao, A. Pu, S. V. Lichtenstein, and C. R. Thompson
Reply
J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1095 - 1096.
[Full Text] [PDF]


Home page
PerfusionHome page
F. Pappalardo, C. Corno, A. Franco, G. Giardina, A.M. Scandroglio, G. Landoni, G. Crescenzi, and A. Zangrillo
Reduction of hemodilution in small adults undergoing open heart surgery: a prospective, randomized trial
Perfusion, September 1, 2007; 22(5): 317 - 322.
[Abstract] [PDF]


Home page
J. Appl. Physiol.Home page
G. M. T. Hare, C. D. Mazer, J. S. Hutchison, A. T. McLaren, E. Liu, A. Rassouli, J. Ai, R. E. Shaye, J. A. Lockwood, C. E. Hawkins, et al.
Severe hemodilutional anemia increases cerebral tissue injury following acute neurotrauma
J Appl Physiol, September 1, 2007; 103(3): 1021 - 1029.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Kulier, J. Levin, R. Moser, G. Rumpold-Seitlinger, I. C. Tudor, S. A. Snyder-Ramos, P. Moehnle, D. T. Mangano, and for the Investigators of the Multicenter Study of
Impact of Preoperative Anemia on Outcome in Patients Undergoing Coronary Artery Bypass Graft Surgery
Circulation, July 31, 2007; 116(5): 471 - 479.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Perthel, L. El-Ayoubi, A. Bendisch, J. Laas, and M. Gerigk
Clinical advantages of using mini-bypass systems in terms of blood product use, postoperative bleeding and air entrainment: an in vivo clinical perspective
Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1070 - 1075.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. A.J.M. Huybregts, A. M. Morariu, G. Rakhorst, S. R. Spiegelenberg, H. W.A. Romijn, R. de Vroege, and W. van Oeveren
Attenuated Renal and Intestinal Injury After Use of a Mini-Cardiopulmonary Bypass System
Ann. Thorac. Surg., May 1, 2007; 83(5): 1760 - 1766.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al.
Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline
Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Ranucci, C. Bellucci, D. Conti, A. Cazzaniga, and B. Maugeri
Determinants of Early Discharge From the Intensive Care Unit After Cardiac Operations
Ann. Thorac. Surg., March 1, 2007; 83(3): 1089 - 1095.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. Castiglioni, A. Verzini, F. Pappalardo, N. Colangelo, L. Torracca, A. Zangrillo, and O. Alfieri
Minimally Invasive Closed Circuit Versus Standard Extracorporeal Circulation for Aortic Valve Replacement
Ann. Thorac. Surg., February 1, 2007; 83(2): 586 - 591.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
M. Perthel, A. Klingbeil, L. El-Ayoubi, M. Gerick, and J. Laas
Reduction in blood product usage associated with routine use of mini bypass systems in extracorporeal circulation
Perfusion, January 1, 2007; 22(1): 9 - 14.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
C. D. Mazer, F. Briet, K. R. Blight, D. J. Stewart, M. Robb, Z. Wang, A. M. Harrington, W. Mak, X. Li, and G. M.T. Hare
Increased cerebral and renal endothelial nitric oxide synthase gene expression after cardiopulmonary bypass in the rat
J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 13 - 20.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. Miura, T. Sakamoto, M. Kobayashi, T. Shin'oka, and H. Kurosawa
Hemodilutional anemia impairs neurologic outcome after cardiopulmonary bypass in a piglet model
J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 29 - 36.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. T. McLaren, P. A. Marsden, C. D. Mazer, A. J. Baker, D. J. Stewart, A. K. Y. Tsui, X. Li, Y. Yucel, M. Robb, S. R. Boyd, et al.
Increased expression of HIF-1{alpha}, nNOS, and VEGF in the cerebral cortex of anemic rats
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R403 - R414.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. J. Murphy and G. D. Angelini
Indications for Blood Transfusion in Cardiac Surgery
Ann. Thorac. Surg., December 1, 2006; 82(6): 2323 - 2334.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
H. Kamiya, T. Kofidis, A. Haverich, and U. Klima
Preliminary experience with the mini-extracorporeal circulation system (Medtronic resting heart system)
Interactive CardioVascular and Thoracic Surgery, December 1, 2006; 5(6): 680 - 682.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
I. Florath, A. Albert, W. Hassanein, B. Arnrich, U. Rosendahl, I. C. Ennker, and J. Ennker
Current determinants of 30-day and 3-month mortality in over 2000 aortic valve replacements: impact of routine laboratory parameters
Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 716 - 721.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
G. M. T. Hare, J. M. A. Worrall, A. J. Baker, E. Liu, N. Sikich, and C. D. Mazer
{beta}2 Adrenergic antagonist inhibits cerebral cortical oxygen delivery after severe haemodilution in rats
Br. J. Anaesth., November 1, 2006; 97(5): 617 - 623.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. J.G. Harrison, J. Stygall, D. C. Whitaker, N. M. Grundy, and S. P. Newman
Hematocrit during cardiopulmonary bypass.
Ann. Thorac. Surg., September 1, 2006; 82(3): 1166 - 1166.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
K. G. Shann, D. S. Likosky, J. M. Murkin, R. A. Baker, Y. R. Baribeau, G. R. DeFoe, T. A. Dickinson, T. J. Gardner, H. P. Grocott, G. T. O'Connor, et al.
An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response.
J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 283 - 290.e3.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Ranucci, G. Isgro, F. Romitti, S. Mele, B. Biagioli, and P. Giomarelli
Anaerobic Metabolism During Cardiopulmonary Bypass: Predictive Value of Carbon Dioxide Derived Parameters
Ann. Thorac. Surg., June 1, 2006; 81(6): 2189 - 2195.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
K. McCusker, A. Chalafant, G. de Foe, S. Gunaydin, and V. Vijay
Influence of hematocrit and pump prime on cerebral oxygen saturation in on-pump coronary revascularization
Perfusion, May 1, 2006; 21(3): 149 - 155.
[Abstract] [PDF]


Home page
Eur Heart JHome page
M. Cladellas, J. Bruguera, J. Comin, J. Vila, E. de Jaime, J. Marti, and M. Gomez
Is pre-operative anaemia a risk marker for in-hospital mortality and morbidity after valve replacement?
Eur. Heart J., May 1, 2006; 27(9): 1093 - 1099.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. S. Shah
Postoperative Renal Dysfunction After On-Pump Versus Off-Pump Coronary Revascularization: Role of On-Pump Hemodilution and Transfusions
Ann. Thorac. Surg., April 1, 2006; 81(4): 1548 - 1549.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Liebold, A. Khosravi, B. Westphal, C. Skrabal, Y.H. Choi, C. Stamm, A. Kaminski, A. Alms, T. Birken, D. Zurakowski, et al.
Effect of closed minimized cardiopulmonary bypass on cerebral tissue oxygenation and microembolization
J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 268 - 276.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Ranucci, F. Romitti, G. Isgro, M. Cotza, S. Brozzi, A. Boncilli, and A. Ditta
Oxygen Delivery During Cardiopulmonary Bypass and Acute Renal Failure After Coronary Operations
Ann. Thorac. Surg., December 1, 2005; 80(6): 2213 - 2220.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. Karkouti, G. Djaiani, M. A. Borger, W. S. Beattie, L. Fedorko, D. Wijeysundera, J. Ivanov, and J. Karski
Low Hematocrit During Cardiopulmonary Bypass is Associated With Increased Risk of Perioperative Stroke in Cardiac Surgery
Ann. Thorac. Surg., October 1, 2005; 80(4): 1381 - 1387.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
R. H. Habib, A. Zacharias, T. A. Schwann, and C. J. Riordan
The independent effects of cardiopulmonary bypass hemodilutional anemia and transfusions on CABG outcomes
Eur. J. Cardiothorac. Surg., September 1, 2005; 28(3): 512 - 513.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Kuduvalli, A. D. Grayson, M. J. Desmond, and B. M. Fabri
Reply to Habib et al.
Eur. J. Cardiothorac. Surg., September 1, 2005; 28(3): 513 - 514.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. Shah
Effects of Obesity and Small Body Size on Operative and Long-Term Outcomes of Coronary Artery Bypass Surgery: A Propensity-Matched Analysis
Ann. Thorac. Surg., June 1, 2005; 79(6): 1976 - 1986.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. H. Edwards, V. A. Ferraris, D. M. Shahian, E. Peterson, A. P. Furnary, C. K. Haan, and C. R. Bridges
Gender-Specific Practice Guidelines for Coronary Artery Bypass Surgery: Perioperative Management
Ann. Thorac. Surg., June 1, 2005; 79(6): 2189 - 2194.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. A. Jonas
Hematocrit trial
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1200 - 1200.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
Y. Ootaki, M. Yamaguchi, and N. Yoshimura
Reply to the Editor
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1201 - 1202.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
K. Karkouti, W.S. Beattie, D.N. Wijeysundera, V. Rao, C. Chan, K.M. Dattilo, G. Djaiani, J. Ivanov, J. Karski, and T.E. David
Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery
J. Thorac. Cardiovasc. Surg., February 1, 2005; 129(2): 391 - 400.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
R. M. Guezuraga and D. Y. Steinbring
View from industry
Eur. J. Cardiothorac. Surg., December 1, 2004; 26(Suppl_1): S19 - S24.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
R. Wynne and M. Botti
Postoperative Pulmonary Dysfunction in Adults After Cardiac Surgery With Cardiopulmonary Bypass: Clinical Significance and Implications for Practice
Am. J. Crit. Care., September 1, 2004; 13(5): 384 - 393.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
Z. Xia, R. Xia, H.-T. Lan, T. Luo, Q.-Z. Tang, Z.-Y. Xia, and X.-Y. Liu
Systemic ischemic preconditioning plus hemodilution enhanced early functional recovery of reperfused heart in the rabbits
Interactive CardioVascular and Thoracic Surgery, September 1, 2004; 3(3): 528 - 532.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. Shah
Worse early outcomes in women after coronary artery bypass grafting: Is it simply a matter of size?
J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 487 - 488.
[Full Text] [PDF]


Home page
PerfusionHome page
R de Vroege, F te Meerman, L Eijsman, W R Wildevuur, C. R. Wildevuur, and W van Oeveren
Induction and detection of disturbed homeostasis in cardiopulmonary bypass
Perfusion, September 1, 2004; 19(5): 267 - 276.
[Abstract] [PDF]


Home page
PerfusionHome page
F. Merkle, W. Boettcher, F. Schulz, A. Koster, M. Huebler, and R. Hetzer
Perfusion technique for nonhaemic cardiopulmonary bypass prime in neonates and infants under 6 kg body weight
Perfusion, July 1, 2004; 19(4): 229 - 237.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. H. Shuhaiber
Intraoperative hematocrit and cardiopulmonary bypass
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1226 - 1227.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. Shah
Reply to the Editor
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1227 - 1228.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Anoar Zacharias
Thomas A. Schwann
Christopher J. Riordan
Samuel J. Durham
Aamir Shah
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Habib, R. H.
Right arrow Articles by Shah, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Habib, R. H.
Right arrow Articles by Shah, A.
Related Collections
Right arrow Cardiac - physiology
Right arrow Extracorporeal circulation


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS